Glaxo Wellcome/Warner-Lambert
Executive Summary
Glaxo regains rights to all future Rx-to-OTC switches, including the antiviral Zovirax and the nasal inhaler Beconase, as part of the dissolution of the Warner-Wellcome joint venture. Warner-Lambert retains rights to OTC Zantac in the U.S. Glaxo explained that it decided to leave the joint venture because of its renewed regional focus, not an abandonment of interest in the OTC market